FT839 in Autoimmune Diseases
Recruiting
Phase 1
Phase 2
Interventional Study
ANCA-Associated Vasculitis (AAV)
Idiopathic Inflammatory Myositis (IIM)
Rheumatoid Arthritis (RA)
Systemic Lupus Erythematosus (SLE)
Systemic Sclerosis (SSc)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 70
- Sex
- Any
- Trial phase
- Phase 1/2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 446 (estimated)
- Sponsor
- Fate Therapeutics · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥18 to ≤70 years
* Must have active B-cell mediated autoimmune disease (AAV, IIM, RA, SLE, or SSc) confirmed by standard criteria
* Moderate to severe disease, requiring at least two prior treatments that were ineffective
* Adequate organ function to tolerate treatment
* A…
Contacts
Natalie Shiff, MD
CONTACT